EUCTR2014-003997-18-BE进行中（未招募）1 期
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Immune Globulin (Human), 10% Caprylate/ Chromatography Purified (IGIV -C) in Symptomatic Subjects with Generalized Myasthenia Gravis
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 62
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male or female, ages 18 to 85 years
- •2. Anti-AChR antibody positive
- •3. Confirmed diagnosis of generalized MG. Historically, subjects may have previously had the Myasthenia Gravis Foundation of America (MGFA) Class II, III, IV, or V.
- •4. MGFA classification of Class II, III, or IVa inclusive at Screening.
- •5. QMG score =10 at Screening. Note: Subjects who only have a history of ocular MG may not enroll.
- •6. Receiving standard of care MG treatment at a stable dose consisting of any one of the following for the time intervals delineated below (time intervals apply to medications and maintenance of stable dose level):
- •-Cholinesterase inhibitor (pyridostigmine or equivalent) for at least 2 weeks prior to Screening and no immunosuppressants
- •- Cholinesterase inhibitor (pyridostigmine or equivalent) for at least 2 weeks priorto Screening and/or only one of the following:
- •* Prednisone (up to 60 mg/day or equivalent) for at least two month prior to Screening, or
- •* Azathioprine for at least 6 months prior to Screening, or
- •* Mycophenolate mofetil for at least 6 months prior to Screening, or
- •* Methotrexate for at least 6 months prior to screening, or
- •* Cyclosporine or tacrolimus for at least 3 months prior to Screening
- •- Cholinesterase inhibitor (pyridostigmine or equivalent) for at least 2 weeks prior to Screening and/or prednisone (up to 60 mg/day or equivalent) for at least one month prior to Screening and only one of the following:
- •* Azathioprine for at least 6 months prior to Screening, or
- •* Mycophenolate mofetil for at least 6 months prior to Screening, or
- •* Methotrexate for at least 6 months prior to screening, or
- •* Cyclosporine or tacrolimus for at least 3 months prior to Screening
- •7. Subjects must be willing and able to provide written informed consent
- •8. Subjects must be willing to comply with all aspects of the clinical trial protocol.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 56
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 6
排除标准
- •1. Have received cyclophosphamide or any other immunosuppressive agent apart from the ones allowed per inclusion criteria within the past 6 months
- •2. Any change in MG treatment regimen between Screening (Week -3, Visit 0) and Baseline (Week 0, Visit 1)
- •3. Greater than two (>2) point change in QMG score, increased or decreased, between Screening (Week -3, Visit 0) and Baseline (Week 0, Visit 1)
- •4. Any episode of myasthenic crisis in the one month prior to Screening
- •5. Evidence of malignancy within the past 5 years (non-melanoma skin cancer, carcinoma in situ of cervix is allowed) or thymoma potentially requiring surgical intervention during the course of the trial (intent to perform thymectomy)
- •6. Thymectomy within the preceding six months
- •7. Rituximab, belimumab, eculizumab or any monoclonal antibody used for immunomodulation within the past 12 months
- •8. Have received immune globulin (Ig) treatment given by IV, subcutaneous, or intramuscular route within the last 3 months
- •9. Current known hyperviscosity or hypercoagulable state
- •10. Currently receiving anti-coagulation therapy (vitamin K antagonists, nonvitamin K antagonist oral anticoagulants [e.g., dabigatran etexilate, rivaroxaban, edoxaban, and apixaban], parenteral anticoagulants [e.g., fondaparinux]). Note that oral anti-platelet agents are allowed (e.g., aspirin, clopidogrel, ticlodipine)
- •11. Plasma exchange (PLEX) performed within the last 3 months
- •12. History of non-response to IVIg when used in maintenance therapy of the subject’s MG, as judged by the Investigator
- •13. Any comorbid condition that in the opinion of the Investigator would put the subject at undue safety risk or compromise the ability of the subject to participate in the trial or the scientific integrity of the study
- •14. Inadequate venous access to support repeated intravenous infusions
- •15. History of anaphylactic reactions or severe reactions to any blood-derived product
- •16. History of intolerance to any component of the IP
- •17. Documented diagnosis of thrombotic complications to polyclonal IVIg therapy in the past
- •18. History of recent (within the last year) myocardial infarction or stroke
- •19. Uncontrolled congestive heart failure; embolism; or historically documented (within the last year) electrocardiogram (ECG) changes indicative of myocardial ischemia or atrial fibrillation
- •20. History of chronic alcoholism or illicit drug abuse (addiction) in the 12 months preceding the Screening/Week -3 (Visit 0)
- •21. Active psychiatric illness that interferes with compliance or communication with health care personnel
- •22. Females of child-bearing potential who are pregnant or have a positive serum pregnancy test (beta-human chorionic gonadotropin [ß-HCG]-based assay)
- •23. Females who are breastfeeding
- •24. Females of child-bearing potential who are unwilling to practice a highly effective method of contraception (oral, injectable or implanted hormonal methods of contraception, placement of an intrauterine device or intrauterine system, condom or occlusive cap with spermicidal foam/gel/film/cream/suppository, male sterilization, or true abstinence*) throughout the study.
- •* True abstinence: When this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [e.g., calendar, ovulation, symptothermal, post-ovulation methods], declaration of abstinence for the duration of a trial, and withdrawal are not acceptable methods of contraception.)
- •25. Currently receiving, or having r
研究者
相似试验
进行中（未招募）
不适用
Study of AMG 785 in Tibial Diaphyseal Fractures Status Post Intramedullary NailingAcceleration of fracture healingMedDRA version: 14.1Level: PTClassification code 10043827Term: Tibia fractureSystem Organ Class: 10022117 - Injury, poisoning and procedural complicationsEUCTR2008-008392-34-DEAmgen Inc400
进行中（未招募）
不适用
Study of AMG785 in hip fractureEUCTR2009-015939-33-FIAmgen Inc330
进行中（未招募）
不适用
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (erlotinib) Following Complete Tumor Resection and with or without Adjuvant Chemotherapy in Patients with Stage IB-IIIA Non-small Cell Lung Carcinoma who have EGFR-positive Tumors - RADIANTStage IB-IIIA Non-small Cell Lung Carcinoma with EGFR-positive tumorsMedDRA version: 16.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2005-001747-29-DEOSI Pharmaceuticals, LLC945
尚未招募
不适用
A Multi-center, Randomized, Double-blind, Placebo-controlled Pilot Study to Evaluate the Efficacy and Safety of Diacerein for Prophylaxis in Patients with Gout who Have Difficulties to Use Colchicine for ProphylaxisKCT0007719Masan Samsung Medical Center54
进行中（未招募）
1 期
A study investigating Immune Globuline (Human), 10% Caprylate/Chromatography Purified (IGIV-C) for the treatment of patients with Myasthenia Gravis. The patients will receive 2g/kg of IP as a loading dose. The loading dosage is followed by maintenance doses of 1 g/kg administered every third week until Visit 8 (Week 21).MedDRA version: 20.0Level: PTClassification code 10028417Term: Myasthenia gravisSystem Organ Class: 10029205 - Nervous system disordersMyasthenia GravisEUCTR2014-003997-18-CZGrifols Therapeutics Inc.62